LogicBio Therapeutics, Inc. (NASDAQ: LOGC) Investor Securities Class Action Lawsuit 03/19/2020

If you purchased a significant amount of shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, and / or if you purchased any NASDAQ: LOGC shares prior to December 2018 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: May 18, 2020. NASDAQ: LOGC investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
LogicBio Therapeutics
Case Name: 
LogicBio Therapeutics Shareholder Class Action Lawsuit 03/19/2020
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: LOGC
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
03/19/2020
Class Period Begin: 
12/03/2018
Class Period End: 
02/10/2020
Court of Filing: 
U.S. District Court for the District of New Jersey
Deadline To File for Lead: 
05/18/2020
Summary: 

An investor in shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by LogicBio Therapeutics, Inc. in connection with certain allegedly false and misleading statements made between December 3, 2018 and February 10, 2020.

Cambridge, MA based LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. On February 10, 2020, post-market, LogicBio Therapeutics, Inc announced that “the U.S. Food and Drug Administration (FDA) has placed a clinical hold on [LogicBio’s] Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions.”

Shares of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) declined from $11.60 per share on February 10, 2020 to as low as $3.05 per share on March 12, 2020.

According to the complaint the plaintiff alleges on behalf of purchasers of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) common shares between December 3, 2018 and February 10, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 3, 2018 and February 10, 2020, the defendants made false and/or misleading statements and/or failed to disclose that: LogicBio's behind-schedule and rushed Investigational New Drug ("IND") submission of LB-001 did not answer certain pertinent clinical and nonclinical questions, that as a result, the U.S. Food and Drug Administration was likely to hold or deny the IND submission of LB-001 for treatment of methylmalonic acidemia (MMA), and that as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.